RT Journal Article
SR Electronic
T1 Pharmacological Properties of Peptides Derived from Stromal Cell-Derived Factor 1: Study on Human Polymorphonuclear Cells
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 1418
OP 1425
DO 10.1124/mol.59.6.1418
VO 59
IS 6
A1 Nikolaus Heveker
A1 Michèle Tissot
A1 Alain Thuret
A1 Jens Schneider-Mergener
A1 Marc Alizon
A1 Monique Roch
A1 Stefano Marullo
YR 2001
UL http://molpharm.aspetjournals.org/content/59/6/1418.abstract
AB Small compounds capable of blocking the stromal cell-derived factor 1 (SDF-1) receptor CXCR4 may be potentially useful as anti-inflammatory, antiallergic, immunomodulatory, and anti-human immunodeficiency virus (HIV) agents. SDF-1–derived peptides have proven to target CXCR4 efficiently despite a 100-fold lower affinity (or more) than SDF-1. Here we studied the binding and antiviral properties of a series of substituted SDF-1–derived N-terminal peptides and tested their functional effects on human polymorphonuclear cells, because these cells are very reactive to chemokines and chemoattractants. All peptides bound to CXCR4 and inhibited HIV entry in a functional assay on CD4+ HeLa cells. A 10-residue substituted dimer, derived from the 5–14 sequence of SDF-1, displayed the highest affinity for CXCR4 (K i value of 290 nM, a reduction of only 15-fold compared with SDF-1) and was also the best competitor for HIV entry (IC50 value of 130 nM). Whereas most peptides displayed CXCR4-independent functional effects on human polymorphonuclear cells, including the modulation of calcium fluxes and the activation of superoxide anion production at high concentration (10 μM), the peptide dimer was devoid of these nonspecific effects at antiviral concentrations. Overall, this study shows that appropriate modifications of SDF-1–derived N-terminal peptides may ameliorate their binding and viral blocking properties without generating significant unspecific side effects.